Literature DB >> 32962403

High cardiovascular risk of patients with type 2 diabetes is only partially attributed to angiographic burden of atherosclerosis.

Simone Battermann1, Andrea Milzi1, Rosalia Dettori1, Kathrin Burgmaier2, Nikolaus Marx1, Mathias Burgmaier1, Sebastian Reith1.   

Abstract

BACKGROUND: Patients with type 2 diabetes (T2DM) are at high risk for cardiovascular events and present more severe coronary artery disease (CAD). The Gensini and COURAGE scores are established angiographic instruments to assess CAD severity, which may also predict future cardiovascular risk. However, it is unclear if these scores are able to depict the increased risk of patients with T2DM and stable CAD (T2DM-SAP).
METHODS: We performed quantitative coronary angiography and assessed the Gensini and COURAGE scores in 124 patients with T2DM-SAP. Angiographic data were compared to patients with stable angina without T2DM (Non-DM-SAP, n = 74), and to patients with acute coronary syndrome and T2DM (T2DM-ACS, n = 53).
RESULTS: T2DM-SAP patients had similar Gensini and COURAGE-scores compared to Non-DM-SAP-patients (Gensini: 14.44 ± 27.34 vs 11.49 ± 26.99, p = 0.465; COURAGE: 3.48 ± 4.49 vs 3.60 ± 4.72, p = 0.854). In contrast, T2DM-SAP patients had significantly lower Gensini (14.44 ± 27.34 vs 30.94 ± 48.74, p = 0.003) and lower COURAGE (3.48 ± 4.49 vs 5.30 ± 4.63, p = 0.016) scores compared to T2DM-ACS-patients.
CONCLUSION: Both the Gensini and the COURAGE score fail to predict the high cardiovascular risk of patients with T2DM-SAP. Therefore, these scores should be used with caution in the assessment of future risk of patients with T2DM. However, among T2DM-ACS patients, both scores are increased, reflecting the high cardiovascular risk in this patient population.

Entities:  

Keywords:  COURAGE score; Gensini score; Quantitative coronary angiography; Type 2 diabetes mellitus; coronary artery disease

Mesh:

Year:  2020        PMID: 32962403      PMCID: PMC7919215          DOI: 10.1177/1479164120953612

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  31 in total

1.  Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial.

Authors:  G B John Mancini; Pamela M Hartigan; Eric R Bates; Bernard R Chaitman; Steven P Sedlis; David J Maron; William J Kostuk; John A Spertus; Koon K Teo; Marcin Dada; Merril Knudtson; Daniel S Berman; David C Booth; William E Boden; William S Weintraub
Journal:  Am Heart J       Date:  2013-08-02       Impact factor: 4.749

Review 2.  The vulnerable myocardium. Diabetic cardiomyopathy.

Authors:  H Bugger; C Bode
Journal:  Hamostaseologie       Date:  2014-11-19       Impact factor: 1.778

3.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

4.  Optical coherence tomography derived differences of plaque characteristics in coronary culprit lesions between type 2 diabetic patients with and without acute coronary syndrome.

Authors:  Sebastian Reith; Simone Battermann; Rainer Hoffmann; Nikolaus Marx; Mathias Burgmaier
Journal:  Catheter Cardiovasc Interv       Date:  2013-11-09       Impact factor: 2.692

5.  Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study.

Authors:  Koji Kato; Taishi Yonetsu; Soo-Joong Kim; Lei Xing; Hang Lee; Iris McNulty; Robert W Yeh; Rahul Sakhuja; Shaosong Zhang; Shiro Uemura; Bo Yu; Kyoichi Mizuno; Ik-Kyung Jang
Journal:  Circ Cardiovasc Imaging       Date:  2012-06-07       Impact factor: 7.792

6.  Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes.

Authors:  Bernt J von Scholten; Philip Hasbak; Thomas E Christensen; Adam A Ghotbi; Andreas Kjaer; Peter Rossing; Tine W Hansen
Journal:  Diabetologia       Date:  2015-11-02       Impact factor: 10.122

7.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

8.  Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people.

Authors:  Anoop Dinesh Shah; Claudia Langenberg; Eleni Rapsomaniki; Spiros Denaxas; Mar Pujades-Rodriguez; Chris P Gale; John Deanfield; Liam Smeeth; Adam Timmis; Harry Hemingway
Journal:  Lancet Diabetes Endocrinol       Date:  2014-11-11       Impact factor: 32.069

9.  Intrinsic calcification angle: a novel feature of the vulnerable coronary plaque in patients with type 2 diabetes: an optical coherence tomography study.

Authors:  Sebastian Reith; Andrea Milzi; Enrico Domenico Lemma; Rosalia Dettori; Kathrin Burgmaier; Nikolaus Marx; Mathias Burgmaier
Journal:  Cardiovasc Diabetol       Date:  2019-09-24       Impact factor: 9.951

10.  Type 2 diabetes mellitus is associated with a lower fibrous cap thickness but has no impact on calcification morphology: an intracoronary optical coherence tomography study.

Authors:  Andrea Milzi; Mathias Burgmaier; Kathrin Burgmaier; Martin Hellmich; Nikolaus Marx; Sebastian Reith
Journal:  Cardiovasc Diabetol       Date:  2017-12-01       Impact factor: 9.951

View more
  1 in total

1.  Cost-effectiveness of screening of coronary artery disease in patients with type 2 DIABetes at a very high cardiovascular risk (SCADIAB study) rational and design.

Authors:  Kamel Mohammedi; Nathalie Préaubert; Tanguy Cariou; Vincent Rigalleau; Ninon Foussard; Laurent Piazza; Céline Bairras-Martin; Thierry Couffinhal; Julien Bezin; Antoine Benard
Journal:  Cardiovasc Diabetol       Date:  2021-03-13       Impact factor: 9.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.